Look At Analyst Expectations For A Better Read On Abbott Laboratories (NYSE: ABT)

Currently, there are 1.73B common shares owned by the public and among those 1.72B shares have been available to trade.

The company’s stock has a 5-day price change of 1.83% and 1.77% over the past three months. ABT shares are trading 1.77% year to date (YTD), with the 12-month market performance up to 13.06% higher. It has a 12-month low price of $89.67 and touched a high of $121.64 over the same period. ABT has an average intraday trading volume of 5.72 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.23%, -2.68%, and 5.18% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Institutional ownership of Abbott Laboratories (NYSE: ABT) shares accounts for 77.13% of the company’s 1.73B shares outstanding.

It has a market capitalization of $194.37B and a beta (3y monthly) value of 0.74. The stock’s trailing 12-month PE ratio is 34.30, while the earnings-per-share (ttm) stands at $3.27. The company has a PEG of 4.40 and a Quick Ratio of 1.16 with the debt-to-equity ratio at 0.41. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.42% over the week and 1.66% over the month.

Analysts forecast that Abbott Laboratories (ABT) will achieve an EPS of $0.96 for the current quarter, $1.12 for the next quarter and $5.09 for 2025. The lowest estimate earnings-per-share for the quarter is $0.94 while analysts give the company a high EPS estimate of $1.01. Comparatively, EPS for the current quarter was $0.94 a year ago. Earnings per share for the fiscal year are expected to increase by 4.05%, and 11.38% over the next financial year. EPS should shrink at an annualized rate of 7.80% over the next five years, compared to 19.65% over the past 5-year period.

Morgan Stanley coverage for the Abbott Laboratories (ABT) stock in a research note released on May 30, 2023 offered a Equal-Weight rating with a price target of $112. Wolfe Research was of a view on April 20, 2023 that the stock is Underperform, while UBS gave the stock Buy rating on April 20, 2023, issuing a price target of $117- $130. Raymond James on their part issued Outperform rating on April 20, 2023.

Most Popular

Related Posts